Literature DB >> 3062540

The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation.

A J Flach1, C J Lavelle, K W Olander, J A Retzlaff, L W Sorenson.   

Abstract

Ketorolac tromethamine solution 0.5% (1 drop 3 times daily) was more effective than the placebo vehicle solution in suppressing postoperative anterior ocular inflammation after extracapsular cataract extraction (ECCE) and intraocular lens (IOL) implantation in this multicenter, double-masked, randomized study. Four of 60 ketorolac-treated patients compared with 25 of 58 placebo-treated patients required supplemental corticosteroid therapy to suppress inflammation in the postoperative period which was statistically significant (P less than 0.001). Even though these supplemental steroid-treated patients were kept in the analysis, the placebo-treated group showed more evidence of anterior ocular inflammation as measured by anterior segment fluorophotometry. This was consistent with slit-lamp observations of increased anterior ocular inflammation. This study supported previous studies that suggested ketorolac tromethamine ophthalmic solution 0.5% was effective and safe as a nonsteroidal anti-inflammatory agent for topical use after ECCE and IOL implantation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3062540     DOI: 10.1016/s0161-6420(88)33034-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  14 in total

Review 1.  The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery.

Authors:  A J Flach
Journal:  Trans Am Ophthalmol Soc       Date:  1998

Review 2.  The emerging roles of topical non-steroidal anti-inflammatory agents in ophthalmology.

Authors:  P Koay
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

3.  Efficacy of systemic diclofenac sodium on intravitreal concentration.

Authors:  Yunes Panahi; Mostafa Naderi; Khosrow Jadidi; Hadise Hoseini; Mojtaba Abrishami
Journal:  Int Ophthalmol       Date:  2017-01-10       Impact factor: 2.031

Review 4.  Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  M M Buckley; R N Brogden
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

5.  Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery.

Authors:  M Nardi; C Lobo; A Bereczki; J Cano; E Zagato; S Potts; G Sullins; R Notivol
Journal:  Clin Ophthalmol       Date:  2007-12

6.  A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery.

Authors:  Helga P Sandoval; Luis E Fernández de Castro; David T Vroman; Kerry D Solomon
Journal:  Clin Ophthalmol       Date:  2007-12

7.  Diabetic cataract-pathogenesis, epidemiology and treatment.

Authors:  Andreas Pollreisz; Ursula Schmidt-Erfurth
Journal:  J Ophthalmol       Date:  2010-06-17       Impact factor: 1.909

8.  The effect of topical sodium diclofenac on macular thickness in diabetic eyes after phacoemulsification: a randomized controlled trial.

Authors:  Morteza Entezari; Alireza Ramezani; Homayon Nikkhah; Mehdi Yaseri
Journal:  Int Ophthalmol       Date:  2016-03-14       Impact factor: 2.031

Review 9.  Clinical pharmacokinetics of ketorolac tromethamine.

Authors:  D R Brocks; F Jamali
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 10.  Non-steroidal anti-inflammatory drugs versus corticosteroids for controlling inflammation after uncomplicated cataract surgery.

Authors:  Viral V Juthani; Elizabeth Clearfield; Roy S Chuck
Journal:  Cochrane Database Syst Rev       Date:  2017-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.